Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study is to determine the safety, tolerability, and activity of
XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a
small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2
(KDR), ErbB2, and EphB4. Sensitivity to EGFR inhibitors has been linked to specific EGFR
mutations and associated with certain clinical characteristics in patients with NSCLC (eg,
female, minimal and remote smoking history, and adenocarcinoma histology).